{
    "abstract": "Introduction Vaccination with formulations containing pneumococcal protein antigens such as pneumolysin toxoid (dPly) and histidine-triad protein D (PhtD) may extend serotype-related protection of pneumococcal conjugate vaccines (PCVs) against Streptococcus pneumoniae. Methods This phase II, multi-center, observer-blind trial conducted in Europe (NCT01204658) assessed 2 investigational vaccines containing 10 serotype-specific polysaccharide conjugates of PHiD-CV and either 10 or 30 \u00b5g of dPly and PhtD each. Infants randomized 1:1:1:1 received 4 doses of PHiD-CV/dPly/PhtD-10, PHiD-CV/dPly/PhtD-30, PHiD-CV, or 13-valent PCV (PCV13), co-administered with DTPa-HBV-IPV/Hib, at ages \u223c2, 3, 4 and 12\u201315 months. Occurrences of fever >40.0 \u00b0C following primary vaccination with PHiD-CV/dPly/PhtD vaccines compared to PHiD-CV (non-inferiority objective), dose superiority, safety and immunogenicity were assessed. Results 575 children received primary vaccination, and 564 booster vaccination. The non-inferiority objective was met; no fever >40.0 \u00b0C causally related to vaccination was reported during primary vaccination. Incidence of adverse events appeared similar between the 3 PHiD-CV groups. Serious adverse events were reported in 13, 9, 21 (1 related to vaccination), and 17 children in the PHiD-CV/dPly/PhtD-10, PHiD-CV/dPly/PhtD-30, PHiD-CV, and PCV13 groups, respectively. PHiD-CV/dPly/PhtD-30 was superior to PHiD-CV/dPly/PhtD-10 in terms of post-dose 3 anti-Ply and Anti-PhtD antibody levels. Anti-Ply and anti-PhtD antibody levels were higher in both PHiD-CV/dPly/PhtD groups than in controls and increased from post-primary to post-booster timepoint. Post-primary and booster vaccination, for each PHiD-CV serotype, \u226598.5% of participants in PHiD-CV/dPly/PhtD groups had antibody concentrations \u2265 0.2 \u03bcg/mL, except for 6B (\u226572.3%) and 23 F (\u226582.7%) post-primary vaccination. Similar results were observed in the PHiD-CV group. Immune responses to protein D and DTPa-HBV-IPV/Hib were within similar ranges for the 3 PHiD-CV groups. Conclusion Both PHiD-CV/dPly/PhtD formulations co-administered with DTPa-HBV-IPV/Hib in infants were well-tolerated and immunogenic for dPly and PhtD antigens, while immune responses to serotype-specific, protein D and co-administered antigens did not appear altered in comparison to PHiD-CV group.",
    "author_highlights": [
        {
            "endOffset": 27323,
            "sentence": "Combined vaccine formulations PHiD-CV with 10 or 30 \u00b5g of dPly and PhtD were assessed.",
            "startOffset": 27237
        },
        {
            "endOffset": 27397,
            "sentence": "They were co-administered with DTPa-HBV-IPV/Hib in infants (3+1 schedule)",
            "startOffset": 27324
        },
        {
            "endOffset": 27480,
            "sentence": "No increase of fever (>40 \u00b0C) post-doses 1\u20133 was demonstrated compared to PHiD-CV.",
            "startOffset": 27398
        },
        {
            "endOffset": 27512,
            "sentence": "No safety concerns were raised.",
            "startOffset": 27481
        },
        {
            "endOffset": 27597,
            "sentence": "dPly/PhtD were immunogenic; post-dose 3 the 30 \u00b5g formulation was superior to 10 \u00b5g.",
            "startOffset": 27513
        },
        {
            "endOffset": 27677,
            "sentence": "Immunogenicity of conjugates and co-administered antigens did not seem altered.",
            "startOffset": 27598
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Lara J.",
                    "initial": "L.J.",
                    "last": "Wolfson"
                },
                {
                    "first": "James P.",
                    "initial": "J.P.",
                    "last": "Watt"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Henkle"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Deloria-Knoll"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "McCall"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Lee"
                },
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Mulholland"
                },
                {
                    "first": "Orin S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Cherian"
                }
            ],
            "doi": "10.1016/S0140-6736(09)61204-6",
            "firstpage": "893",
            "issn": "01406736",
            "lastpage": "902",
            "pmid": "19748398",
            "pub_year": 2009,
            "title": "Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates",
            "volume": "374"
        },
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "J. R.",
                    "initial": "J.R.",
                    "last": "Catterall"
                }
            ],
            "firstpage": "929",
            "issn": "00406376",
            "lastpage": "937",
            "pmid": "10491458",
            "pub_year": 1999,
            "title": "Streptococcus pneumoniae",
            "volume": "54"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Ewald"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Briel"
                },
                {
                    "first": "Danielle",
                    "initial": "D.",
                    "last": "Vuichard"
                },
                {
                    "first": "Veronika",
                    "initial": "V.",
                    "last": "Kreutle"
                },
                {
                    "first": "Andriy",
                    "initial": "A.",
                    "last": "Zhydkov"
                },
                {
                    "first": "Viktoria",
                    "initial": "V.",
                    "last": "Gloy"
                }
            ],
            "doi": "10.3238/arztebl.2016.0139",
            "firstpage": "93",
            "issn": "18660452",
            "lastpage": "104",
            "pmid": "26987462",
            "pub_year": 2016,
            "title": "Clinical efficacy of pneumococcal conjugate vaccines",
            "volume": "113"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Adoraci\u00f3n Navarro",
                    "initial": "A.N.",
                    "last": "Torn\u00e9"
                },
                {
                    "first": "Joana Gomes",
                    "initial": "J.G.",
                    "last": "Dias"
                },
                {
                    "first": "Chantal",
                    "initial": "C.",
                    "last": "Quinten"
                },
                {
                    "first": "Frantiska",
                    "initial": "F.",
                    "last": "Hruba"
                },
                {
                    "first": "Marta Cecilia",
                    "initial": "M.C.",
                    "last": "Busana"
                },
                {
                    "first": "Pier Luigi",
                    "initial": "P.L.",
                    "last": "Lopalco"
                },
                {
                    "first": "Andrew J.Amato",
                    "initial": "A.J.A.",
                    "last": "Gauci"
                },
                {
                    "first": "Lucia",
                    "initial": "L.",
                    "last": "Pastore-Celentano"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Sabbe"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Verhaegen"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Koliou"
                },
                {
                    "first": "Despo",
                    "initial": "D.",
                    "last": "Pieridou-Bagkatzouni"
                },
                {
                    "first": "Pavla",
                    "initial": "P.",
                    "last": "K\u0159i\u017eov\u00e0"
                },
                {
                    "first": "Jana",
                    "initial": "J.",
                    "last": "Kozakova"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Motlova"
                },
                {
                    "first": "Palle",
                    "initial": "P.",
                    "last": "Valentiner-Branth"
                },
                {
                    "first": "Lotte",
                    "initial": "L.",
                    "last": "Lambertsen"
                },
                {
                    "first": "Theano",
                    "initial": "T.",
                    "last": "Georgakopoulou"
                },
                {
                    "first": "Hilary",
                    "initial": "H.",
                    "last": "Humphreys"
                },
                {
                    "first": "Tanya",
                    "initial": "T.",
                    "last": "Melillo"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Caruana"
                },
                {
                    "first": "Mirjam",
                    "initial": "M.",
                    "last": "Knol"
                },
                {
                    "first": "Hester",
                    "initial": "H.",
                    "last": "de Merkel"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Elberse"
                },
                {
                    "first": "Didrik",
                    "initial": "D.",
                    "last": "Frimann"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Skoczynska"
                },
                {
                    "first": "Waleria",
                    "initial": "W.",
                    "last": "Hryniewicz"
                },
                {
                    "first": "Alicja",
                    "initial": "A.",
                    "last": "Kuch"
                },
                {
                    "first": "Iwona",
                    "initial": "I.",
                    "last": "Paradowska-Stankiewicz"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Pana"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Vitek"
                },
                {
                    "first": "Veronika",
                    "initial": "V.",
                    "last": "U\u010dakar"
                },
                {
                    "first": "Birgitta Henriques",
                    "initial": "B.H.",
                    "last": "Normark"
                },
                {
                    "first": "Tiia",
                    "initial": "T.",
                    "last": "Lepp"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Slack"
                },
                {
                    "first": "Pauline A.",
                    "initial": "P.A.",
                    "last": "Waight"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.04.066",
            "firstpage": "3644",
            "issn": "0264410X",
            "lastpage": "3650",
            "pmid": "24795228",
            "pub_year": 2014,
            "title": "European enhanced surveillance of invasive pneumococcal disease in 2010: Data from 26 European countries in the post-heptavalent conjugate vaccine era",
            "volume": "32"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Daniel M.",
                    "initial": "D.M.",
                    "last": "Weinberger"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Malley"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lipsitch"
                }
            ],
            "doi": "10.1016/S0140-6736(10)62225-8",
            "firstpage": "1962",
            "issn": "01406736",
            "lastpage": "1973",
            "pmid": "21492929",
            "pub_year": 2011,
            "title": "Serotype replacement in disease after pneumococcal vaccination",
            "volume": "378"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Amy Sarah",
                    "initial": "A.S.",
                    "last": "Ginsburg"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                },
                {
                    "first": "Farukh M.",
                    "initial": "F.M.",
                    "last": "Khambaty"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1586/erv.12.5",
            "firstpage": "279",
            "issn": "14760584",
            "lastpage": "285",
            "pmid": "22380821",
            "pub_year": 2012,
            "title": "Issues and challenges in the development of pneumococcal protein vaccines",
            "volume": "11"
        },
        "b0040": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "M. O.",
                    "initial": "M.O.",
                    "last": "Ota"
                },
                {
                    "first": "E. O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Owiafe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1080/21645515.2015.1111496",
            "firstpage": "393",
            "issn": "21645515",
            "lastpage": "402",
            "pmid": "26618243",
            "pub_year": 2016,
            "title": "Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2\u20134\u00a0years: A phase II randomized study",
            "volume": "12"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Pazdiora"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.03.066",
            "firstpage": "3025",
            "issn": "0264410X",
            "lastpage": "3034",
            "pmid": "24699466",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial",
            "volume": "32"
        },
        "b0050": {
            "authors": [
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Olivier"
                },
                {
                    "first": "B. H.",
                    "initial": "B.H.",
                    "last": "Belohradsky"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Stojanov"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Bonnet"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Petersen"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Liese"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.11.096",
            "firstpage": "3142",
            "issn": "0264410X",
            "lastpage": "3152",
            "pmid": "18502545",
            "pub_year": 2008,
            "title": "Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants",
            "volume": "26"
        },
        "b0055": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Habermehl"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Cimino"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Petersen"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.03.032",
            "firstpage": "4727",
            "issn": "0264410X",
            "lastpage": "4736",
            "pmid": "16616973",
            "pub_year": 2006,
            "title": "Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants",
            "volume": "24"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Cathy",
                    "initial": "C.",
                    "last": "Maes"
                },
                {
                    "first": "Fien",
                    "initial": "F.",
                    "last": "De Boever"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.02.052",
            "firstpage": "6838",
            "issn": "0264410X",
            "lastpage": "6846",
            "pmid": "24607003",
            "pub_year": 2014,
            "title": "Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study",
            "volume": "32"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1586/erv.09.113",
            "firstpage": "1479",
            "issn": "14760584",
            "lastpage": "1500",
            "pmid": "19863240",
            "pub_year": 2009,
            "title": "10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix\u2122",
            "volume": "8"
        },
        "b0070": {
            "authors": [
                {
                    "first": "A. Sahib Mehdi",
                    "initial": "A.S.M.",
                    "last": "El-Radhi"
                }
            ],
            "doi": "10.1136/adc.2008.139949",
            "firstpage": "918",
            "issn": "00039888",
            "lastpage": "920",
            "pmid": "18562453",
            "pub_year": 2008,
            "title": "Why is the evidence not affecting the practice of fever management?",
            "volume": "93"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Chevallier"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Jerzy",
                    "initial": "J.",
                    "last": "Brzostek"
                },
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Bermal"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Aristegui"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Cleerbout"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f62d",
            "firstpage": "S109",
            "issn": "08913668",
            "lastpage": "S118",
            "pmid": "19325447",
            "pub_year": 2009,
            "title": "Safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines",
            "volume": "28"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Bryony",
                    "initial": "B.",
                    "last": "Hicks"
                },
                {
                    "first": "Garvin",
                    "initial": "G.",
                    "last": "Bixler"
                },
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Hou"
                },
                {
                    "first": "Vildana",
                    "initial": "V.",
                    "last": "Pehlic"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Yuan"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.076",
            "firstpage": "7461",
            "issn": "0264410X",
            "lastpage": "7468",
            "pmid": "23123106",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine",
            "volume": "30"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Seiberling"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Brookes"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Ochs"
                },
                {
                    "first": "Kerry",
                    "initial": "K.",
                    "last": "Go"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Lashley"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Yuan"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.080",
            "firstpage": "7455",
            "issn": "0264410X",
            "lastpage": "7460",
            "pmid": "23131206",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults",
            "volume": "30"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Branda",
                    "initial": "B.",
                    "last": "Hu"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Nicolas",
                    "initial": "N.",
                    "last": "Corde"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Pouzet"
                },
                {
                    "first": "Gloria",
                    "initial": "G.",
                    "last": "Zimmermann"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.005",
            "firstpage": "327",
            "issn": "0264410X",
            "lastpage": "333",
            "pmid": "23153437",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults",
            "volume": "31"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Holmlund"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiambao"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Ollgren"
                },
                {
                    "first": "Teija",
                    "initial": "T.",
                    "last": "Jaakkola"
                },
                {
                    "first": "C\u00e9cile",
                    "initial": "C.",
                    "last": "Neyt"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1128/CVI.00050-09",
            "firstpage": "916",
            "issn": "15566811",
            "lastpage": "923",
            "pmid": "19403781",
            "pub_year": 2009,
            "title": "Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in filipino pregnant women and their infants in relation to pneumococcal carriage",
            "volume": "16"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Holmlund"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiambao"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Ollgren"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.07.055",
            "firstpage": "57",
            "issn": "0264410X",
            "lastpage": "65",
            "pmid": "16115703",
            "pub_year": 2006,
            "title": "Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin a and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage",
            "volume": "24"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Satu",
                    "initial": "S.",
                    "last": "Rapola"
                },
                {
                    "first": "Virva",
                    "initial": "V.",
                    "last": "Jantti"
                },
                {
                    "first": "Raili",
                    "initial": "R.",
                    "last": "Haikala"
                },
                {
                    "first": "Ritva",
                    "initial": "R.",
                    "last": "Syrjanen"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                },
                {
                    "first": "Jacquelyn S.",
                    "initial": "J.S.",
                    "last": "Sampson"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Briles"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Paton"
                },
                {
                    "first": "Aino K.",
                    "initial": "A.K.",
                    "last": "Takala"
                },
                {
                    "first": "Terhi M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Kayhty"
                }
            ],
            "doi": "10.1086/315822",
            "firstpage": "1146",
            "issn": "00221899",
            "lastpage": "1152",
            "pmid": "10979911",
            "pub_year": 2000,
            "title": "Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media",
            "volume": "182"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Aderonke",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "Martin O.C.",
                    "initial": "M.O.C.",
                    "last": "Ota"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Ezra O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "Yauba",
                    "initial": "Y.",
                    "last": "Saidu"
                },
                {
                    "first": "Ebenezer",
                    "initial": "E.",
                    "last": "Foster-Nyarko"
                },
                {
                    "first": "Patrick K.",
                    "initial": "P.K.",
                    "last": "Owiafe"
                },
                {
                    "first": "Fatima",
                    "initial": "F.",
                    "last": "Ceesay"
                },
                {
                    "first": "Archibald",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "Olubukola T.",
                    "initial": "O.T.",
                    "last": "Idoko"
                },
                {
                    "first": "Olumuyiwa",
                    "initial": "O.",
                    "last": "Owolabi"
                },
                {
                    "first": "Abdoulie",
                    "initial": "A.",
                    "last": "Bojang"
                },
                {
                    "first": "Sheikh",
                    "initial": "S.",
                    "last": "Jarju"
                },
                {
                    "first": "Isatou",
                    "initial": "I.",
                    "last": "Drammeh"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Brian M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Devos"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Schoonbroodt"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Swinnen"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.071",
            "firstpage": "2531",
            "issn": "0264410X",
            "lastpage": "2542",
            "pmid": "28389097",
            "pub_year": 2017,
            "title": "Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study",
            "volume": "35"
        },
        "b0115": {
            "authors": [
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Adamou"
                },
                {
                    "first": "J. H.",
                    "initial": "J.H.",
                    "last": "Heinrichs"
                },
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Erwin"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Walsh"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Gayle"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Dormitzer"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Dagan"
                },
                {
                    "first": "Y. A.",
                    "initial": "Y.A.",
                    "last": "Brewah"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Barren"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Lathigra"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Langermann"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Koenig"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.1128/IAI.69.2.949-958.2001",
            "firstpage": "949",
            "issn": "00199567",
            "lastpage": "958",
            "pmid": "11159990",
            "pub_year": 2001,
            "title": "Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis",
            "volume": "69"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Godfroid"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.01.085",
            "firstpage": "6451",
            "issn": "0264410X",
            "lastpage": "6453",
            "pmid": "21315695",
            "pub_year": 2011,
            "title": "Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides",
            "volume": "29"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Mario T.",
                    "initial": "M.T.",
                    "last": "Philipp"
                },
                {
                    "first": "Lara",
                    "initial": "L.",
                    "last": "Doyle"
                },
                {
                    "first": "Dale",
                    "initial": "D.",
                    "last": "Martin"
                },
                {
                    "first": "Georges",
                    "initial": "G.",
                    "last": "Carletti"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.05.051",
            "firstpage": "5495",
            "issn": "0264410X",
            "lastpage": "5501",
            "pmid": "21624422",
            "pub_year": 2011,
            "title": "A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae",
            "volume": "29"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Mar\u00eda",
                    "initial": "M.",
                    "last": "Del Mar Garc\u00eda-Su\u00e1rez"
                },
                {
                    "first": "Mar\u00eda Dolores",
                    "initial": "M.D.",
                    "last": "Cima-Cabal"
                },
                {
                    "first": "Noelia",
                    "initial": "N.",
                    "last": "Fl\u00f3rez"
                },
                {
                    "first": "Pilar",
                    "initial": "P.",
                    "last": "Garc\u00eda"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Cernuda-Cernuda"
                },
                {
                    "first": "Aurora",
                    "initial": "A.",
                    "last": "Astudillo"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "V\u00e1zquez"
                },
                {
                    "first": "Juan R.",
                    "initial": "J.R.",
                    "last": "De Los Toyos"
                },
                {
                    "first": "F. Javier",
                    "initial": "F.J.",
                    "last": "M\u00e9ndez"
                }
            ],
            "doi": "10.1128/IAI.72.8.4534-4540.2004",
            "firstpage": "4534",
            "issn": "00199567",
            "lastpage": "4540",
            "pmid": "15271913",
            "pub_year": 2004,
            "title": "Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin",
            "volume": "72"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Godfroid"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1128/IAI.00378-10",
            "firstpage": "238",
            "issn": "00199567",
            "lastpage": "245",
            "pmid": "20956575",
            "pub_year": 2011,
            "title": "Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens",
            "volume": "79"
        },
        "b0140": null,
        "b0145": {
            "authors": [
                {
                    "first": "Abiodun D.",
                    "initial": "A.D.",
                    "last": "Ogunniyi"
                },
                {
                    "first": "Marcin",
                    "initial": "M.",
                    "last": "Grabowicz"
                },
                {
                    "first": "Layla K.",
                    "initial": "L.K.",
                    "last": "Mahdi"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Cook"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Gordon"
                },
                {
                    "first": "Tania A.",
                    "initial": "T.A.",
                    "last": "Sadlon"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Paton"
                }
            ],
            "doi": "10.1096/fj.08-119537",
            "firstpage": "731",
            "issn": "08926638",
            "lastpage": "738",
            "pmid": "18971260",
            "pub_year": 2009,
            "title": "Pneumococcal histidine triad proteins are regulated by the Zn2+ -dependent repressor AdcR and inhibit complement deposition through the recruitment of complement Factor H",
            "volume": "23"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Leszek",
                    "initial": "L.",
                    "last": "Szenborn"
                },
                {
                    "first": "Masnuel",
                    "initial": "M.",
                    "last": "Moro"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Petit"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Bermal"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Bernard"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f61b",
            "firstpage": "S97",
            "issn": "08913668",
            "lastpage": "S108",
            "pmid": "19325452",
            "pub_year": 2009,
            "title": "Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV)",
            "volume": "28"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Peeters"
                },
                {
                    "first": "Viktor",
                    "initial": "V.",
                    "last": "Chrobok"
                },
                {
                    "first": "Pavla",
                    "initial": "P.",
                    "last": "Kriz"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Novakova"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Kaliskova"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Jean Paul",
                    "initial": "J.P.",
                    "last": "Prieels"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1016/S0140-6736(06)68304-9",
            "firstpage": "740",
            "issn": "01406736",
            "lastpage": "748",
            "pmid": "16517274",
            "pub_year": 2006,
            "title": "Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study",
            "volume": "367"
        },
        "b0160": null
    },
    "body_text": [
        {
            "endOffset": 47023,
            "parents": [],
            "secId": "s0075",
            "sentence": "In both PHiD-CV/dPly/PhtD groups, one month post-primary vaccination, anti-Ply antibody GMCs increased compared to baseline and anti-PhtD antibody GMCs remained at least at pre-vaccination levels.",
            "startOffset": 46827,
            "title": "Discussion"
        },
        {
            "endOffset": 53891,
            "parents": [],
            "secId": "s0105",
            "sentence": "Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Fran\u00e7ois N, Gardev A, Borys D. Immunogenicity of primary vaccination with an investigational protein-based pneumococcal vaccine in infants in Europe: a phase II randomized trial. [",
            "startOffset": 53650,
            "title": "Previous publications"
        },
        {
            "endOffset": 42244,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "One month post-primary vaccination, for 8 out of the 10 common serotypes (except 6B and 23F), at least 98.5% of infants in the PHiD-CV/dPly/PhtD groups, and at least 97.7% and 96.2% in the PHiD-CV and PCV13 groups had antibody concentrations \u2265 0.2 \u03bcg/mL (Table S4).",
            "startOffset": 41979,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 39515,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Vaccination-related unsolicited symptoms were reported for none of the PHiD-CV/dPly/PhtD vaccinees, for 1.4% of PHiD-CV, and 0.7% of PCV13 vaccinees.",
            "startOffset": 39366,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38279,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "No apparent increases in the incidences of solicited local and general symptoms were observed following consecutive doses of either PHiD-CV/dPly/PhtD-10 or PHiD-CV/dPly/PhtD-30 during the primary vaccination period, but there was a trend towards higher incidences following booster vaccination (Fig. 2).",
            "startOffset": 37976,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43687,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "Increases in OPA titers were observed for each PHiD-CV serotype following primary and booster doses in the PHiD-CV/dPly/PhtD groups, as well as in the control groups.",
            "startOffset": 43521,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 52720,
            "parents": [],
            "secId": "s0100",
            "sentence": "GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 52577,
            "title": "Funding"
        },
        {
            "endOffset": 36084,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Large swelling reactions were solicited post-booster, and serious adverse events (SAEs) throughout the entire study (Text S2).",
            "startOffset": 35958,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 46164,
            "parents": [],
            "secId": "s0075",
            "sentence": "No fatal SAEs were reported in this study.",
            "startOffset": 46122,
            "title": "Discussion"
        },
        {
            "endOffset": 45606,
            "parents": [],
            "secId": "s0075",
            "sentence": "The current study demonstrated that the addition of Ply and PhtD to the PHiD-CV formulation does not significantly increase incidences of post-vaccination fever >40.0 \u00b0C compared to the licensed PHiD-CV, when co-administered with DTPa-HBV-IPV/Hib, which is a vaccine commonly included in pediatric immunization programs.",
            "startOffset": 45286,
            "title": "Discussion"
        },
        {
            "endOffset": 37676,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Local grade 3 symptom incidence remained under 6% following each dose in all groups.",
            "startOffset": 37592,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37975,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Irritability was the most frequently reported general symptom for both primary (after 55.0%\u201356.6% of doses) and booster (59.0%\u201366.0%) vaccination in all groups (Fig. 2C).",
            "startOffset": 37805,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41350,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "For PhtD, antibody GMCs increased 1 month post-primary vaccination only in PHiD-CV/dPly/PhtD groups.",
            "startOffset": 41250,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 40627,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Higher anti-Ply and anti-PhtD antibody geometric mean concentrations (GMCs) were observed following vaccination with PHiD-CV/dPly/PhtD-30 than with the PHiD-CV/dPly/PhtD-10 formulation.",
            "startOffset": 40442,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 45147,
            "parents": [],
            "secId": "s0075",
            "sentence": "This is the first study assessing the safety and reactogenicity of 2 investigational vaccine formulations combining pneumococcal proteins with the 10 conjugated PHiD-CV polysaccharides administered according to a 3+1 schedule in infants 6\u201314 weeks of age at first vaccination.",
            "startOffset": 44871,
            "title": "Discussion"
        },
        {
            "endOffset": 33493,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 33377,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40441,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Superiority of PHiD-CV/dPly/PhtD-30 over PHiD-CV/dPly/PhtD-10 in terms of post-dose 3 antibody concentrations against Ply and against PhtD was demonstrated (Table 1).",
            "startOffset": 40275,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 47239,
            "parents": [],
            "secId": "s0075",
            "sentence": "The levels remained elevated 8 months post-dose 3 in PHiD-CV/dPly/PhtD vaccinees, while in control groups, they stayed below baseline at all timepoints, but followed different kinetics for each pneumococcal protein.",
            "startOffset": 47024,
            "title": "Discussion"
        },
        {
            "endOffset": 39996,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "One hypotonic-hyporesponsive episode on the day of the first PHiD-CV dose was considered causally related to vaccination; the event resolved without sequelae after 6 days.",
            "startOffset": 39825,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 50240,
            "parents": [],
            "secId": "s0075",
            "sentence": "Lastly, anti-Ply and anti-PhtD antibody concentrations were determined through an assay not calibrated for values expressed in \u03bcg/mL, so a comparison with data reported in SI units is not possible.",
            "startOffset": 50043,
            "title": "Discussion"
        },
        {
            "endOffset": 41535,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "In all groups, pre-booster vaccination, anti-PhtD antibody GMCs tended to be lower than baseline values, and in control groups lower values than post-primary vaccination were observed.",
            "startOffset": 41351,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 37804,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Symptoms at pneumococcal vaccines or DTPa-HBV-IPV/Hib injection sites had similar incidences across all groups (Fig. 2A and B).",
            "startOffset": 37677,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 42523,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "For serotypes 19A, 6A, and 3, the percentages of infants with antibody concentrations \u2265 0.2 \u03bcg/mL were at least 96.2% in the PCV13 group, while in the 3 PHiD-CV groups, the percentages ranged between 46.3\u201346.9% for serotype 19A, 31.8\u201333.8% for 6A, and 10.8\u201313.6% for serotype 3.",
            "startOffset": 42245,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 39793,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "SAEs were reported for 56 children during the primary vaccination course (12 in PHiD-CV/dPly/PhtD-10 group, 9 in PHiD-CV/dPly/PhtD-30 group, 21 in PHiD-CV group, and 14 in PCV13 group), and for 4 in the post-booster period (1 in PHiD-CV/dPly/PhtD-10 group and 3 in PCV13 group).",
            "startOffset": 39515,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 30446,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 30445,
                    "startOffset": 30442
                }
            },
            "secId": "s0005",
            "sentence": "Three licensed pneumococcal conjugated vaccines (PCVs) contain polysaccharides of 7, 10, or 13 pneumococcal serotypes out of the more than 90 known [3].",
            "startOffset": 30294,
            "title": "Introduction"
        },
        {
            "endOffset": 53361,
            "parents": [],
            "secId": "s0105",
            "sentence": "IDWeek - 743] (poster).",
            "startOffset": 53338,
            "title": "Previous publications"
        },
        {
            "endOffset": 38803,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "During primary vaccination, at least 1 unsolicited symptom was reported after 16.9% of PHiD-CV/dPly/PhtD-10 and 21.4% of PHiD-CV/dPly/PhtD-30 doses, and after 20.1% of PHiD-CV and 20.0% of PCV13 doses (Table S3).",
            "startOffset": 38591,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37230,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "No fever >40.0 \u00b0C was reported during the primary vaccination for any of the 4 groups, thus non-inferiority criteria were met, as the null hypothesis was ruled out with a 1-sided p-value of 0.003.",
            "startOffset": 37034,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39824,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "No fatal events were reported.",
            "startOffset": 39794,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41691,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Following booster dose, anti-PhtD antibody GMCs increased in both PHiD-CV/dPly/PhtD groups, while they remained below baseline in control groups (Table 2).",
            "startOffset": 41536,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 48948,
            "parents": [],
            "secId": "s0075",
            "sentence": "The study has several strengths.",
            "startOffset": 48916,
            "title": "Discussion"
        },
        {
            "endOffset": 51625,
            "parents": [],
            "secId": "s0090",
            "sentence": "S.A. Silfverdal has received board membership payment in 2008-2012 from the GSK Sweden Advisory Board on pneumococcal vaccines.",
            "startOffset": 51498,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 45714,
            "parents": [],
            "secId": "s0075",
            "sentence": "The reactogenicity profile of both PHiD-CV/dPly/PhtD formulations appeared to be similar to that of PHiD-CV.",
            "startOffset": 45606,
            "title": "Discussion"
        },
        {
            "endOffset": 31891,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study assessed the safety, reactogenicity and immunogenicity of 2 investigational vaccine formulations, containing either 10 or 30 \u00b5g of dPly and PhtD each and the serotype-specific polysaccharide conjugates of the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix, GSK, Belgium), when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa, GSK, Belgium) to healthy infants.",
            "startOffset": 31466,
            "title": "Introduction"
        },
        {
            "endOffset": 47397,
            "parents": [],
            "secId": "s0075",
            "sentence": "A strong booster effect for Ply and PhtD antibodies was observed in the PHiD-CV/dPly/PhtD groups, especially following vaccination with PHiD-CV/dPly/PhtD-30.",
            "startOffset": 47240,
            "title": "Discussion"
        },
        {
            "endOffset": 30796,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 30795,
                    "startOffset": 30792
                }
            },
            "secId": "s0005",
            "sentence": "The use of conserved pneumococcal protein antigens in next-generation vaccines could potentially provide protection against S. pneumoniae regardless of the capsular serotypes [7].",
            "startOffset": 30617,
            "title": "Introduction"
        },
        {
            "endOffset": 51880,
            "parents": [],
            "secId": "s0090",
            "sentence": "P. Albrecht reports grants and grants for participation in conferences and honoraria as speaker from Pfizer, MSD and GSK group of companies outside the submitted work.",
            "startOffset": 51713,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 49575,
            "parents": [],
            "secId": "s0075",
            "sentence": "Although functional assays for pneumococcal protein antibodies may be better suited to characterize immune response, they were not available at the time of the analysis.",
            "startOffset": 49406,
            "title": "Discussion"
        },
        {
            "endOffset": 34363,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "All groups received DTPa-HBV-IPV/Hib concomitantly at each vaccination visit.",
            "startOffset": 34286,
            "title": "Study vaccines"
        },
        {
            "endOffset": 42654,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "In all groups, for each PHiD-CV serotype, antibody GMCs were higher post-primary and post-booster vaccination compared to baseline.",
            "startOffset": 42523,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 31363,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 31275,
                    "startOffset": 31268
                },
                "b0055": {
                    "endOffset": 31275,
                    "startOffset": 31268
                }
            },
            "secId": "s0005",
            "sentence": "This increases the risk of post-immunization febrile reactions and febrile seizures [10,11] and in consequence may require use of antipyretics, medical visits, or hospitalization.",
            "startOffset": 31184,
            "title": "Introduction"
        },
        {
            "endOffset": 32789,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Treatment allocation at the investigator site was performed using an internet central randomization system.",
            "startOffset": 32682,
            "title": "Study design and participants"
        },
        {
            "endOffset": 50776,
            "parents": [],
            "secId": "s0080",
            "sentence": "Immune responses to vaccine pneumococcal serotypes and to co-administered DTPa-HBV-IPV/Hib vaccine antigens elicited in PHiD-CV/dPly/PhtD groups did not appear altered in comparison to those in the PHiD-CV group.",
            "startOffset": 50564,
            "title": "Conclusions"
        },
        {
            "endOffset": 43521,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "One month post-primary vaccination, for each of the 10 PHiD-CV serotypes, at least 88.9% and 91.1% of infants in PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 groups had OPA titers \u22658, except for serotype 1 (66.7% and 57.9%, respectively), while this percentage was \u226587.7% in the PHiD-CV group and \u226588.9% in the PCV13 group, except for serotype 1 (61.5% and 83.9% respectively) (Table S5).",
            "startOffset": 43132,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 47472,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 47471,
                    "startOffset": 47467
                }
            },
            "secId": "s0075",
            "sentence": "A similar observation was made in another infant study in the Gambia [22].",
            "startOffset": 47398,
            "title": "Discussion"
        },
        {
            "endOffset": 33888,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at ClinicalTrials.gov (NCT01204658) and available at http://www.gsk-clinicalstudyregister.com (ID: 113994).",
            "startOffset": 33757,
            "title": "Study design and participants"
        },
        {
            "endOffset": 48272,
            "parents": [],
            "secId": "s0075",
            "sentence": "Immune responses against the 10 PHiD-CV serotypes following administration of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 were in the same ranges as those induced by the PHiD-CV vaccine.",
            "startOffset": 48084,
            "title": "Discussion"
        },
        {
            "endOffset": 48574,
            "parents": [],
            "secId": "s0075",
            "sentence": "We did not observe any interference in the immune response induced by DTPa-HBV-IPV/Hib when co-administered with PHiD-CV/dPly/PhtD vaccines.",
            "startOffset": 48434,
            "title": "Discussion"
        },
        {
            "endOffset": 48759,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 48758,
                    "startOffset": 48754
                }
            },
            "secId": "s0075",
            "sentence": "Immune responses against DTPa-HBV-IPV/Hib components did not seem to differ between the 3 PHiD-CV groups and were in line with previous results for co-administration with PHiD-CV [30].",
            "startOffset": 48575,
            "title": "Discussion"
        },
        {
            "endOffset": 52069,
            "parents": [],
            "secId": "s0090",
            "sentence": "A. Gardev was employed by the GSK group of companies.",
            "startOffset": 52016,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 32681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy infants aged 6\u201314 weeks at the time of first vaccination were randomized (1:1:1:1) to receive PHiD-CV/dPly/PhtD-10, PHiD-CV/dPly/PhtD-30, PHiD-CV, or the 13-valent PCV (PCV13; Prevenar 13TM, Pfizer).",
            "startOffset": 32474,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45954,
            "parents": [],
            "secId": "s0075",
            "sentence": "No apparent increased reactogenicity was observed after consecutive primary doses of the vaccines, while post-booster dose, incidences of local and general solicited symptoms seemed to be higher than those observed for primary vaccination.",
            "startOffset": 45715,
            "title": "Discussion"
        },
        {
            "endOffset": 49188,
            "parents": [],
            "secId": "s0075",
            "sentence": "The study was designed to demonstrate 2 confirmatory objectives.",
            "startOffset": 49124,
            "title": "Discussion"
        },
        {
            "endOffset": 37591,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Post-primary vaccination, the most frequently reported local symptom at the pneumococcal vaccine injection site was redness in all groups (after 33.6%\u201338.1% of vaccine doses); post-booster vaccination, redness in the PHiD-CV/dPly/PhtD-10 (47.9%) and PHiD-CV (41.0%) groups, and pain in the PHiD-CV/dPly/PhtD-30 (45.7%) and PCV13 (44.3%) groups were most common.",
            "startOffset": 37230,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 34165,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Control groups received PHiD-CV or PCV13.",
            "startOffset": 34124,
            "title": "Study vaccines"
        },
        {
            "endOffset": 43007,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "For serotypes 19A and 6A, an increase in antibody GMCs across timepoints was evident post-booster vaccination, for all PHiD-CV groups.",
            "startOffset": 42873,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 50042,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 50041,
                    "startOffset": 50037
                }
            },
            "secId": "s0075",
            "sentence": "No statistical comparisons between the 2 comparator vaccines were carried out, and OPA testing was performed in a limited subset of participants; therefore, comparison of the 2 licensed PCVs and OPA results should be interpreted with caution, bearing also in mind that the clinical relevance of the difference in immunogenicity profiles of these vaccines remains unknown and that evidence has grown on the comparability of their effect on pneumococcal diseases [32].",
            "startOffset": 49576,
            "title": "Discussion"
        },
        {
            "endOffset": 36147,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "AE intensity was graded on a scale from 1 (mild) to 3 (severe).",
            "startOffset": 36084,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 46373,
            "parents": [],
            "secId": "s0075",
            "sentence": "The induction of immune responses against Ply and PhtD by both investigational PHiD-CV/dPly/PhtD vaccines post primary vaccination seemed to be dose-dependent, with a higher response for the 30 \u00b5g formulation.",
            "startOffset": 46164,
            "title": "Discussion"
        },
        {
            "endOffset": 36227,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All solicited local reactions were considered causally related to vaccinations.",
            "startOffset": 36148,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 45285,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 45284,
                    "startOffset": 45280
                }
            },
            "secId": "s0075",
            "sentence": "In the context of pediatric vaccination, the occurrence of fever post-vaccination is a major concern for both parents and physicians [14].",
            "startOffset": 45147,
            "title": "Discussion"
        },
        {
            "endOffset": 32174,
            "parents": [],
            "secId": "s0005",
            "sentence": "The primary objectives of the study were to compare the pneumococcal protein-containing vaccines to PHiD-CV with respect to the occurrence of febrile reactions (rectal temperature >40.0 \u00b0C) with causal relationship to primary vaccination, using pre-defined non-inferiority criteria.",
            "startOffset": 31892,
            "title": "Introduction"
        },
        {
            "endOffset": 37006,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Demographic characteristics were similar between all groups (Table S2).",
            "startOffset": 36935,
            "title": "Demographics"
        },
        {
            "endOffset": 31103,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 31055,
                    "startOffset": 31052
                },
                "b0045": {
                    "endOffset": 31102,
                    "startOffset": 31099
                }
            },
            "secId": "s0005",
            "sentence": "Two investigational vaccine formulations containing pneumolysin toxoid (dPly) and pneumococcal histidine-triad protein D (PhtD) have been shown to be well-tolerated and immunogenic when administered as a single dose to 2\u20134 year-old children in The Gambia [8], or as a 2+1 schedule to European toddlers [9].",
            "startOffset": 30797,
            "title": "Introduction"
        },
        {
            "endOffset": 36520,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Sera were stored at \u221220 \u00b0C until analysis.",
            "startOffset": 36478,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 36296,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The causality of all the other AEs was assessed by the investigator.",
            "startOffset": 36228,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 39162,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At least 1 unsolicited symptom assessed by the investigator to be causally related to vaccination was reported after 0.2% and 0.5% of doses for PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 groups, 0.9% for PHiD-CV, and 0.2% for the PCV13 group.",
            "startOffset": 38917,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40258,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Four SAEs not causally related to vaccination did not resolve by study end (2 cases of psychomotor retardation in PHiD-CV/dPly/PhtD-10 and PHiD-CV groups each, 1 type I diabetes mellitus in the PHiD-CV/dPly/PhtD-30 group, and 1 thermal burn in the PCV13 group).",
            "startOffset": 39997,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 53935,
            "parents": [],
            "secId": "s0105",
            "sentence": "2014;3:92.",
            "startOffset": 53925,
            "title": "Previous publications"
        },
        {
            "endOffset": 36934,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Out of the 576 enrolled infants, 575 were included in the total vaccinated cohort of primary vaccination, and 537 in the immunogenicity according-to-protocol cohort; the booster total vaccinated cohort counted 564 toddlers, of which 527 were included in the immunogenicity according-to-protocol cohort (Fig. 1).",
            "startOffset": 36623,
            "title": "Demographics"
        },
        {
            "endOffset": 44860,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "Immune responses to the co-administered DTPa-HBV-IPV/Hib vaccine did not seem to differ across the 4 groups in terms of seropositivity rates or antibody levels, except for anti-tetanus post-booster antibody GMC, which was lower in the PCV13 group than in the 3 PHiD-CV groups (Table S6).",
            "startOffset": 44573,
            "title": "DTPa-HBV-IPV/Hib"
        },
        {
            "endOffset": 35142,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The objectives were assessed sequentially.",
            "startOffset": 35100,
            "title": "Outcomes"
        },
        {
            "endOffset": 49405,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 49404,
                    "startOffset": 49400
                }
            },
            "secId": "s0075",
            "sentence": "Study limitations include the fact that, for the pneumococcal proteins, immunogenicity assessment was carried out by measuring antibody levels, for which the correlate of protection has not yet been established [31].",
            "startOffset": 49189,
            "title": "Discussion"
        },
        {
            "endOffset": 44178,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "The percentage of infants with anti-protein D antibody concentrations \u2265 100 ELISA Units (EL.U)/mL increased from 12 to 19% pre-vaccination to at least 93.4% in the PHiD-CV groups and 40.9% in the PCV13 group post-primary vaccination.",
            "startOffset": 43945,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 31183,
            "parents": [],
            "secId": "s0005",
            "sentence": "Currently, in infant vaccination programs, several vaccines are co-administered.",
            "startOffset": 31103,
            "title": "Introduction"
        },
        {
            "endOffset": 35099,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Non-inferiority of PHiD-CV/dPly/PhtD formulations to PHiD-CV was to be demonstrated if an increase in the percentage of infants with rectally measured temperature >40.0 \u00b0C causally related to primary vaccination above 5% plus half the incidence in the PHiD-CV group (null hypothesis) was ruled out with a 1-sided p-value < 0.05.",
            "startOffset": 34771,
            "title": "Outcomes"
        },
        {
            "endOffset": 46121,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 46120,
                    "startOffset": 46116
                }
            },
            "secId": "s0075",
            "sentence": "Incidences of unsolicited AEs appeared similar within the 3 PHiD-CV groups, and in line with previous reports on PHiD-CV co-administration with DTPa-HBV-IPV/Hib [15].",
            "startOffset": 45955,
            "title": "Discussion"
        },
        {
            "endOffset": 34770,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The second co-primary objective compared PHiD-CV/dPly/PhtD-30 to PHiD-CV in the same manner.",
            "startOffset": 34678,
            "title": "Outcomes"
        },
        {
            "endOffset": 51050,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "Prevenar 13/ Prevnar 13 is a trademark of Pfizer Inc.",
            "startOffset": 50997,
            "title": "Trademark statement"
        },
        {
            "endOffset": 40854,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "At all timepoints, all children in the PHiD-CV/dPly/PhtD groups were seropositive for Ply and PhtD, whereas in the control groups, not all were seropositive for PhtD during the booster phase (Table 2).",
            "startOffset": 40653,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 51712,
            "parents": [],
            "secId": "s0090",
            "sentence": "J. Wysocki reports grants from GSK group of companies during the conduct of the study.",
            "startOffset": 51626,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 53640,
            "parents": [],
            "secId": "s0105",
            "sentence": "2014;3:116.",
            "startOffset": 53629,
            "title": "Previous publications"
        },
        {
            "endOffset": 34479,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Vaccines were administered intramuscularly into the right (pneumococcal vaccines) or left thigh (DTPa-HBV-IPV/Hib).",
            "startOffset": 34364,
            "title": "Study vaccines"
        },
        {
            "endOffset": 50901,
            "parents": [],
            "secId": "s0080",
            "sentence": "Both formulations had a clinically acceptable profile with regard to tolerability and immunogenicity, comparable to PHiD-CV.",
            "startOffset": 50777,
            "title": "Conclusions"
        },
        {
            "endOffset": 36553,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assays are detailed in Table S1.",
            "startOffset": 36521,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 33756,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol, amendments, and informed consent forms were reviewed and approved by national/regional Independent Ethics Committees.",
            "startOffset": 33619,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36600,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Statistical analyses are described in Text S2.",
            "startOffset": 36554,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 34286,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Vaccines were administered at 6\u201314 weeks, 3 and 4 months of age (primary doses), and 12\u201315 months of age (booster dose).",
            "startOffset": 34166,
            "title": "Study vaccines"
        },
        {
            "endOffset": 35501,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The first confirmatory secondary objective compared the PHiD-CV/dPly/PhtD formulations; superiority of one formulation over the other was to be demonstrated post-primary vaccination, if the upper limits of the 95% confidence intervals for the geometric mean concentration (GMC) ratio (10 \u00b5g/30 \u00b5g or 30 \u00b5g/10 \u00b5g) for anti-Ply and anti-PhtD antibodies were <1.",
            "startOffset": 35142,
            "title": "Outcomes"
        },
        {
            "endOffset": 51497,
            "parents": [],
            "secId": "s0090",
            "sentence": "L. Szenborn reports grants from GSK group of companies during the conduct of the study and grants for participation in conferences and honoraria as speaker from Sanofi Pasteur, Pfizer, Novartis and GSK group of companies outside the submitted work.",
            "startOffset": 51249,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 46645,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 46516,
                    "startOffset": 46513
                },
                "b0080": {
                    "endOffset": 46631,
                    "startOffset": 46624
                },
                "b0085": {
                    "endOffset": 46631,
                    "startOffset": 46624
                },
                "b0090": {
                    "endOffset": 46644,
                    "startOffset": 46640
                }
            },
            "secId": "s0075",
            "sentence": "This result complements previous studies assessing immune response induced by the 2 formulations against pneumococcal proteins in toddlers [9] and is in agreement with observations made in adults for other vaccines containing different doses of PhtD [16,17] or dPly [18].",
            "startOffset": 46374,
            "title": "Discussion"
        },
        {
            "endOffset": 52801,
            "parents": [],
            "secId": "s0105",
            "sentence": "The results of this study were presented in part as follows:",
            "startOffset": 52741,
            "title": "Previous publications"
        },
        {
            "endOffset": 32396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase II, randomized, multicenter, observer-blind, controlled study was conducted in the Czech Republic, Germany, Poland and Sweden between 24 September 2010 and 1 October 2012.",
            "startOffset": 32214,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53091,
            "parents": [],
            "secId": "s0105",
            "sentence": "Abstract IDWeek - 745] (poster).",
            "startOffset": 53059,
            "title": "Previous publications"
        },
        {
            "endOffset": 34677,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The first co-primary objective was to compare PHiD-CV/dPly/PhtD-10 to PHiD-CV with respect to the occurrence of febrile reactions (fever >40.0 \u00b0C) causally related to primary vaccination.",
            "startOffset": 34490,
            "title": "Outcomes"
        },
        {
            "endOffset": 41249,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "In control groups, antibody GMCs declined from baseline to post-primary vaccination and tended to increase again at the subsequent timepoints, although values remained below the baseline.",
            "startOffset": 41062,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 51248,
            "parents": [],
            "secId": "s0090",
            "sentence": "R. Prymula reports grants from GSK group of companies during the conduct of the study and grants from GSK group of companies, Novartis, Sanofi Pasteur outside the submitted work.",
            "startOffset": 51070,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 53059,
            "parents": [],
            "secId": "s0105",
            "sentence": "Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Traskine M, Gardev A, Song Y, Borys D. Safety and reactogenicity of the booster dose of 2 investigational protein-based pneumococcal vaccine formulations in toddlers: a phase II randomized trial. [",
            "startOffset": 52801,
            "title": "Previous publications"
        },
        {
            "endOffset": 30294,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 30293,
                    "startOffset": 30288
                },
                "b0010": {
                    "endOffset": 30293,
                    "startOffset": 30288
                }
            },
            "secId": "s0005",
            "sentence": "Streptococcus pneumoniae causes severe infectious diseases such as meningitis, bacteremia and pneumonia, and common illnesses including sinusitis and otitis media [1,2].",
            "startOffset": 30125,
            "title": "Introduction"
        },
        {
            "endOffset": 52576,
            "parents": [],
            "secId": "s0100",
            "sentence": "GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis.",
            "startOffset": 52457,
            "title": "Funding"
        },
        {
            "endOffset": 38591,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Post-booster dose, no large swelling reactions at the injection site of the investigational vaccines were reported, while 6 cases were reported for other vaccines (4 for DTPa-HBV-IPB/Hib, 1 for PHiD-CV and 1 for PCV13).",
            "startOffset": 38372,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 49123,
            "parents": [],
            "secId": "s0075",
            "sentence": "High compliance rates with the protocol-defined procedures, including vaccination schedules, were observed, which supports the validity of safety and immunogenicity analyses.",
            "startOffset": 48949,
            "title": "Discussion"
        },
        {
            "endOffset": 46826,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 46825,
                    "startOffset": 46818
                },
                "b0100": {
                    "endOffset": 46825,
                    "startOffset": 46818
                },
                "b0105": {
                    "endOffset": 46825,
                    "startOffset": 46818
                }
            },
            "secId": "s0075",
            "sentence": "Pre-vaccination levels of anti-Ply and anti-PhtD antibodies in infants in control groups declined post-primary vaccination, likely due to the waning of maternal antibodies [19\u201321].",
            "startOffset": 46646,
            "title": "Discussion"
        },
        {
            "endOffset": 36477,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Blood samples were collected pre-vaccination, 1 month post-dose 3, pre-booster (8\u201311 months post-primary vaccination) and 1 month post-booster (Fig. S1).",
            "startOffset": 36324,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 47953,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 47952,
                    "startOffset": 47948
                },
                "b0115": {
                    "endOffset": 47826,
                    "startOffset": 47819
                },
                "b0120": {
                    "endOffset": 47826,
                    "startOffset": 47819
                },
                "b0125": {
                    "endOffset": 47826,
                    "startOffset": 47819
                },
                "b0130": {
                    "endOffset": 47826,
                    "startOffset": 47819
                },
                "b0135": {
                    "endOffset": 47826,
                    "startOffset": 47819
                },
                "b0140": {
                    "endOffset": 47826,
                    "startOffset": 47819
                },
                "b0145": {
                    "endOffset": 47826,
                    "startOffset": 47819
                }
            },
            "secId": "s0075",
            "sentence": "Although protective effect of pneumococcal Ply and PhtD proteins against lethal challenge, pneumonia or colonization has been well documented in animals [23\u201329], no effect of immunization with pneumococcal proteins on nasopharyngeal colonization was observed in the Gambian infants [22].",
            "startOffset": 47666,
            "title": "Discussion"
        },
        {
            "endOffset": 34123,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 34122,
                    "startOffset": 34113
                },
                "b0060": {
                    "endOffset": 34122,
                    "startOffset": 34113
                },
                "b0065": {
                    "endOffset": 34122,
                    "startOffset": 34113
                }
            },
            "secId": "s0020",
            "sentence": "The 2 investigational formulations contained, in addition to the conjugated polysaccharides of PHiD-CV, dPly and PhtD either at 10 \u03bcg of each (PHiD-CV/dPly/PhtD-10) or at 30 \u03bcg of each (PHiD-CV/dPly/PhtD-30) [8,12,13].",
            "startOffset": 33905,
            "title": "Study vaccines"
        },
        {
            "endOffset": 53338,
            "parents": [],
            "secId": "s0105",
            "sentence": "Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Traskine M, Gardev A, Song Y, Borys D. Immunogenicity of the booster dose of 2 investigational protein-based pneumococcal vaccine formulations in toddlers: a phase II randomized trial. [",
            "startOffset": 53091,
            "title": "Previous publications"
        },
        {
            "endOffset": 41061,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "In both PHiD-CV/dPly/PhtD groups, anti-Ply antibody GMCs increased from pre- to post-primary vaccination, remained higher than baseline levels up to booster vaccination, and mounted again post-booster dose.",
            "startOffset": 40855,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 43945,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "There was no apparent increase in OPA titers for serotype 3 in PHiD-CV groups, following subsequent vaccine doses (Table 4).",
            "startOffset": 43821,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 53924,
            "parents": [],
            "secId": "s0105",
            "sentence": "Abstract ISPPD - 0551] Pneumonia.",
            "startOffset": 53891,
            "title": "Previous publications"
        },
        {
            "endOffset": 33025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Sub-randomization to generate serology subsets comprising \u00b150% of participants from each group for the analyses of opsonophagocytic activity (OPA) and of immune responses to co-administered vaccine components was done at GSK using SAS.",
            "startOffset": 32790,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33274,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Due to differences in physical appearance of the study vaccines, the study was conducted in an observer-blind manner, meaning that vaccine recipients, persons evaluating study endpoints, and laboratory staff were unaware of the vaccine administered.",
            "startOffset": 33025,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33377,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Authorized medical personnel with no further role in the study prepared and administered the vaccines.",
            "startOffset": 33275,
            "title": "Study design and participants"
        },
        {
            "endOffset": 41938,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "At any timepoint, higher GMCs for Ply and PhtD antibodies were observed in the PHiD-CV/dPly/PhtD groups than in control groups as a consequence of immune response in the PHiD-CV/dPly/PhtD groups and decreased antibody level in the control groups.",
            "startOffset": 41692,
            "title": "Pneumococcal proteins"
        },
        {
            "endOffset": 50996,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "Synflorix and Infanrix hexa are trademarks of the GSK group of companies.",
            "startOffset": 50923,
            "title": "Trademark statement"
        },
        {
            "endOffset": 31466,
            "parents": [],
            "secId": "s0005",
            "sentence": "New antigens or vaccines should not increase reactogenicity when they are combined or co-administered.",
            "startOffset": 31364,
            "title": "Introduction"
        },
        {
            "endOffset": 33618,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from the infants\u2019 parents or legally accepted representatives before study enrollment.",
            "startOffset": 33494,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38372,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Most solicited symptoms were reported within the first 4 days of each vaccination (Fig. S2).",
            "startOffset": 38280,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 53595,
            "parents": [],
            "secId": "s0105",
            "sentence": "Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Fran\u00e7ois N, Gardev A, Borys D. Safety and reactogenicity of 2 formulations of an investigational protein-based pneumococcal vaccine in infants in Europe: a phase II trial. [",
            "startOffset": 53361,
            "title": "Previous publications"
        },
        {
            "endOffset": 42872,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "Pre-booster, for each PHiD-CV serotype, antibody GMCs had decreased but remained above baseline levels, except for 6B in PHiD-CV groups, for which an increasing trend in antibody GMCs over time was observed (Table 3).",
            "startOffset": 42655,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 38916,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The most frequently reported unsolicited symptoms were conjunctivitis, bronchitis, nasopharyngitis and rhinitis.",
            "startOffset": 38804,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 50563,
            "parents": [],
            "secId": "s0080",
            "sentence": "PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 formulations co-administered with DTPa-HBV-IPV/Hib according to a 3+1 schedule during the first two years of life have shown a similar reactogenicity profile as the licensed PHiD-CV in terms of incidence of febrile reactions causally related to primary vaccination.",
            "startOffset": 50252,
            "title": "Conclusions"
        },
        {
            "endOffset": 53628,
            "parents": [],
            "secId": "s0105",
            "sentence": "Abstract ISPPD - 0167] Pneumonia.",
            "startOffset": 53595,
            "title": "Previous publications"
        },
        {
            "endOffset": 53650,
            "parents": [],
            "secId": "s0105",
            "sentence": "(poster).",
            "startOffset": 53641,
            "title": "Previous publications"
        },
        {
            "endOffset": 44552,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "anti-PD antibody GMC values in the 3 PHiD-CV groups increased following primary and booster vaccination, and were higher than those in the PCV13 group at all post-vaccination timepoints (Table 3).",
            "startOffset": 44356,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 48916,
            "parents": [],
            "secId": "s0075",
            "sentence": "This result, together with the safety assessment, suggests that both PHiD-CV/dPly/PhtD formulations can be co-administered with DTPa-HBV-IPV/Hib in infants.",
            "startOffset": 48760,
            "title": "Discussion"
        },
        {
            "endOffset": 53951,
            "parents": [],
            "secId": "s0105",
            "sentence": "(presentation).",
            "startOffset": 53936,
            "title": "Previous publications"
        },
        {
            "endOffset": 35719,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Other secondary objectives assessed immune responses to pneumococcal proteins, pneumococcal serotype-specific polysaccharides, protein D, and DTPa-HBV-IPV/Hib, as well as safety and reactogenicity in all study groups.",
            "startOffset": 35502,
            "title": "Outcomes"
        },
        {
            "endOffset": 44355,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "Pre-booster dose, these percentages ranged between 95.4 and 97.7% for groups receiving protein D-containing formulations, and decreased to 28.7% for the PCV13 group (Table S4).",
            "startOffset": 44179,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 52450,
            "parents": [],
            "secId": "s0095",
            "sentence": "Study Conception, Design, Planning: D. Borys, M. Traskine, R. Prymula, S.A. Silfverdal; Collection, Assembling Data: P. Albrecht, J. Wysocki, S.A. Silfverdal; Performing, Supervising Analysis: P. Albrecht, D. Borys, M. Traskine, R. Prymula; Interpretation of Results: P. Albrecht, A. Gardev, D. Borys, M. Traskine, R. Prymula, L. Szenborn, Y. Song, J. Wysocki.",
            "startOffset": 52090,
            "title": "Author\u2019s contribution"
        },
        {
            "endOffset": 47665,
            "parents": [],
            "secId": "s0075",
            "sentence": "However, no correlates of protection in terms of magnitude of immune responses against pneumococcal proteins have been established yet, so the clinical significance of this finding is unknown.",
            "startOffset": 47473,
            "title": "Discussion"
        },
        {
            "endOffset": 32473,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Inclusion/exclusion criteria are detailed in Supplementary Material, Text S1.",
            "startOffset": 32396,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35957,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local and general symptoms occurring within 7 days after each vaccination, and unsolicited adverse events (AEs) occurring within 31 days after each vaccination were recorded on diary cards.",
            "startOffset": 35758,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 48434,
            "parents": [],
            "secId": "s0075",
            "sentence": "Addition of dPly and PhtD in quantities of either 10 or 30 \u03bcg each to the PHiD-CV polysaccharides did not appear to impact immune responses to vaccine serotypes.",
            "startOffset": 48273,
            "title": "Discussion"
        },
        {
            "endOffset": 48084,
            "parents": [],
            "secId": "s0075",
            "sentence": "Another study has been ongoing to determine an effect on clinical disease endpoints such as AOM (ClinicalTrials.gov, NCT01545375).",
            "startOffset": 47954,
            "title": "Discussion"
        },
        {
            "endOffset": 39365,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Post-booster vaccination, at least 1 unsolicited symptom was reported for 27.8% and 18.6% of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 recipients, for 19.3% of PHiD-CV, and 24.3% of PCV13 recipients.",
            "startOffset": 39162,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43132,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "In the PCV13 group, antibody GMCs increased post-primary and post-booster vaccination for serotypes 19A, 6A and 3 (Table 3).",
            "startOffset": 43008,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 52015,
            "parents": [],
            "secId": "s0090",
            "sentence": "D. Borys owns restricted shares of the GSK group of companies.",
            "startOffset": 51953,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 30617,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 30545,
                    "startOffset": 30540
                },
                "b0025": {
                    "endOffset": 30545,
                    "startOffset": 30540
                },
                "b0030": {
                    "endOffset": 30616,
                    "startOffset": 30613
                }
            },
            "secId": "s0005",
            "sentence": "Although these PCVs have significantly decreased the burden of invasive pneumococcal disease [4,5], the incidence of non-vaccine pneumococcal serotypes has increased [6].",
            "startOffset": 30447,
            "title": "Introduction"
        },
        {
            "endOffset": 43820,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "For serotype 6A, an increase in OPA titers post-booster dose with respect to primary vaccination was observed in all PHiD-CV groups.",
            "startOffset": 43688,
            "title": "Pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 51952,
            "parents": [],
            "secId": "s0090",
            "sentence": "M. Traskine, Y. Song, D. Borys are employees of GSK group of companies.",
            "startOffset": 51881,
            "title": "Conflict of interest"
        }
    ],
    "docId": "S0264410X17309040",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "prymula@fnhk.cz",
                "first": "Roman",
                "initial": "R.",
                "last": "Prymula"
            },
            {
                "email": "leszek.szenborn@umed.wroc.pl",
                "first": "Leszek",
                "initial": "L.",
                "last": "Szenborn"
            },
            {
                "email": "sven.arne.silfverdal@umu.se",
                "first": "Sven Arne",
                "initial": "S.A.",
                "last": "Silfverdal"
            },
            {
                "email": "jwysocki@ump.edu.pl",
                "first": "Jacek",
                "initial": "J.",
                "last": "Wysocki"
            },
            {
                "email": "dr.piotr.albrecht@gmail.com",
                "first": "Piotr",
                "initial": "P.",
                "last": "Albrecht"
            },
            {
                "email": "magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": "agardev@gmail.com",
                "first": "Asparuh",
                "initial": "A.",
                "last": "Gardev"
            },
            {
                "email": "yue.x.song@gsk.com",
                "first": "Yue",
                "initial": "Y.",
                "last": "Song"
            },
            {
                "email": "dorota.d.borys@gsk.com",
                "first": "Dorota",
                "initial": "D.",
                "last": "Borys"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.07.008",
        "firstpage": "4603",
        "issn": "0264410X",
        "keywords": [
            "Immunogenicity",
            "Infants",
            "PHiD-CV vaccination",
            "PhtD",
            "Pneumococcal protein",
            "Reactogenicity",
            "dPly"
        ],
        "lastpage": "4611",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants"
    }
}